



公告日期	2025/12/9
異動類別	藥品變更
異動原因	包裝變更
異動描述	<p>Denosumab inj 120mg/1.7mL/vial (Xgeva[®])癌骨瓦注射液因劑型變更，將改以Denosumab inj 120mg/mL/syringe (Xgeva[®])癌骨瓦預充填針筒注射劑替代。</p> <ul style="list-style-type: none"> 舊品用罄，啟用新品。

異動內容		
	舊藥品	新藥品
料號	243556	243557
學名	Denosumab	
商品名	Xgeva	
中文名	癌骨瓦注射液	癌骨瓦預充填針筒注射劑
主成份及含量	120mg/1.7mL/vial	120mg/mL/syringe
製造廠名稱	Amgen Manufacturing Ltd (安進)	Amgen Manufacturing Limited LLC
產地	波多黎各	波多黎各
健保代碼	KC009242FO	KC01288209
外觀/圖檔	 	 
用法	皮下注射	
小孩劑量	<p>Giant cell tumor of bone: Adolescents (skeletally mature) ?45 kg: 120 mg SC q4w; during the first month, give an additional dose of 120 mg on days 8 and 15</p>	<p>Giant cell tumor of bone: Adolescents (<u>skeletally mature</u>) ?45 kg: 120 mg SC Q4W; during the first month, administer an additional 120 mg SC on days 8 and 15</p>

成人劑量	Multiple myeloma: 120 mg SC q4w Bone metastases from solid tumors: 120 mg SC q4w Hypercalcemia of malignancy, Giant cell tumor of bone : 120 mg SC q4w; during the first month, give an additional 120 mg on days 8 and 15	Multiple myeloma, Bone metastases from solid tumors: 120 mg SC Q4W Hypercalcemia of malignancy, Giant cell tumor of bone : 120 mg SC Q4W; during the first month, administer an additional 120 mg SC on days 8 and 15
副作用		